The abnormal status of uncarboxylated matrix Gla protein species represents an additional mortality risk in heart failure patients with vascular disease

Otto, Jr. Mayer; Jitka Seidlerova; Jiri Vanek; Petra Karnosova; Jan Bruthans; Jan Filipovsky; Peter Wohlfahrt; Renata Cifkova; Jindra Windrichova; Maria Knapen; Nadja E. A. Drummen; Cees Vermeer

doi:10.1016/j.ijcard.2015.10.226

The abnormal status of uncarboxylated matrix Gla protein species represents an additional mortality risk in heart failure patients with vascular disease

Otto, Jr. Mayer^*, Jitka Seidlerova, Jiri Vanek, Petra Karnosova, Jan Bruthans, Jan Filipovsky, Peter Wohlfahrt, Renata Cifkova, Jindra Windrichova, Maria Knapen, Nadja E. A. Drummen, Cees Vermeer

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: Matrix Gla protein (MGP) is a natural inhibitor of tissue calcification. In a previous study, we observed the positive association between abnormal concentrations of uncarboxylatedMGP species and increased mortality risk in stable vascular patients. We explore whether co-incidence of abnormal status of uncarboxylated MPG and heart failure (HF) affects the mortality risk. Methods: We examined 799 patients (mean age 65.1 years) with stable vascular disease and followed them in a prospective study. Both, desphospho-uncarboxylated and total uncarboxylated MGP (dp-ucMGP or t-ucMGP) were quantified by pre-commercial ELISA assays. Results: Elevated (>100 ng/L) circulating brain natriuretic peptide (BNP) and abnormal status of plasma uncarboxylated MGP species (i.e.: dp-ucMGP >= 977 pmol/L or t-ucMGP

Original language	English
Pages (from-to)	916-922
Journal	International Journal of Cardiology
Volume	203
DOIs	https://doi.org/10.1016/j.ijcard.2015.10.226
Publication status	Published - 15 Jan 2016

Keywords

Matrix gamma-carboxyl glutamate protein (MGP)
Heart failure
dp-ucMGP
t-ucMGP
Mortality
Atherovascular disease

Access to Document

10.1016/j.ijcard.2015.10.226

Cite this

Mayer, O. J., Seidlerova, J., Vanek, J., Karnosova, P., Bruthans, J., Filipovsky, J., Wohlfahrt, P., Cifkova, R., Windrichova, J., Knapen, M., Drummen, N. E. A., & Vermeer, C. (2016). The abnormal status of uncarboxylated matrix Gla protein species represents an additional mortality risk in heart failure patients with vascular disease. International Journal of Cardiology, 203, 916-922. https://doi.org/10.1016/j.ijcard.2015.10.226

@article{10272fc9d7994130b34b9a6f7ff36b4d,

title = "The abnormal status of uncarboxylated matrix Gla protein species represents an additional mortality risk in heart failure patients with vascular disease",

abstract = "Background: Matrix Gla protein (MGP) is a natural inhibitor of tissue calcification. In a previous study, we observed the positive association between abnormal concentrations of uncarboxylatedMGP species and increased mortality risk in stable vascular patients. We explore whether co-incidence of abnormal status of uncarboxylated MPG and heart failure (HF) affects the mortality risk. Methods: We examined 799 patients (mean age 65.1 years) with stable vascular disease and followed them in a prospective study. Both, desphospho-uncarboxylated and total uncarboxylated MGP (dp-ucMGP or t-ucMGP) were quantified by pre-commercial ELISA assays. Results: Elevated (>100 ng/L) circulating brain natriuretic peptide (BNP) and abnormal status of plasma uncarboxylated MGP species (i.e.: dp-ucMGP >= 977 pmol/L or t-ucMGP ",

keywords = "Matrix gamma-carboxyl glutamate protein (MGP), Heart failure, dp-ucMGP, t-ucMGP, Mortality, Atherovascular disease",

author = "Mayer, {Otto, Jr.} and Jitka Seidlerova and Jiri Vanek and Petra Karnosova and Jan Bruthans and Jan Filipovsky and Peter Wohlfahrt and Renata Cifkova and Jindra Windrichova and Maria Knapen and Drummen, {Nadja E. A.} and Cees Vermeer",

year = "2016",

month = jan,

day = "15",

doi = "10.1016/j.ijcard.2015.10.226",

language = "English",

volume = "203",

pages = "916--922",

journal = "International Journal of Cardiology",

issn = "0167-5273",

publisher = "Elsevier Ireland Ltd",

}

Mayer, OJ, Seidlerova, J, Vanek, J, Karnosova, P, Bruthans, J, Filipovsky, J, Wohlfahrt, P, Cifkova, R, Windrichova, J, Knapen, M, Drummen, NEA & Vermeer, C 2016, 'The abnormal status of uncarboxylated matrix Gla protein species represents an additional mortality risk in heart failure patients with vascular disease', International Journal of Cardiology, vol. 203, pp. 916-922. https://doi.org/10.1016/j.ijcard.2015.10.226

TY - JOUR

T1 - The abnormal status of uncarboxylated matrix Gla protein species represents an additional mortality risk in heart failure patients with vascular disease

AU - Mayer, Otto, Jr.

AU - Seidlerova, Jitka

AU - Vanek, Jiri

AU - Karnosova, Petra

AU - Bruthans, Jan

AU - Filipovsky, Jan

AU - Wohlfahrt, Peter

AU - Cifkova, Renata

AU - Windrichova, Jindra

AU - Knapen, Maria

AU - Drummen, Nadja E. A.

AU - Vermeer, Cees

PY - 2016/1/15

Y1 - 2016/1/15

N2 - Background: Matrix Gla protein (MGP) is a natural inhibitor of tissue calcification. In a previous study, we observed the positive association between abnormal concentrations of uncarboxylatedMGP species and increased mortality risk in stable vascular patients. We explore whether co-incidence of abnormal status of uncarboxylated MPG and heart failure (HF) affects the mortality risk. Methods: We examined 799 patients (mean age 65.1 years) with stable vascular disease and followed them in a prospective study. Both, desphospho-uncarboxylated and total uncarboxylated MGP (dp-ucMGP or t-ucMGP) were quantified by pre-commercial ELISA assays. Results: Elevated (>100 ng/L) circulating brain natriuretic peptide (BNP) and abnormal status of plasma uncarboxylated MGP species (i.e.: dp-ucMGP >= 977 pmol/L or t-ucMGP

AB - Background: Matrix Gla protein (MGP) is a natural inhibitor of tissue calcification. In a previous study, we observed the positive association between abnormal concentrations of uncarboxylatedMGP species and increased mortality risk in stable vascular patients. We explore whether co-incidence of abnormal status of uncarboxylated MPG and heart failure (HF) affects the mortality risk. Methods: We examined 799 patients (mean age 65.1 years) with stable vascular disease and followed them in a prospective study. Both, desphospho-uncarboxylated and total uncarboxylated MGP (dp-ucMGP or t-ucMGP) were quantified by pre-commercial ELISA assays. Results: Elevated (>100 ng/L) circulating brain natriuretic peptide (BNP) and abnormal status of plasma uncarboxylated MGP species (i.e.: dp-ucMGP >= 977 pmol/L or t-ucMGP

KW - Matrix gamma-carboxyl glutamate protein (MGP)

KW - Heart failure

KW - dp-ucMGP

KW - t-ucMGP

KW - Mortality

KW - Atherovascular disease

U2 - 10.1016/j.ijcard.2015.10.226

DO - 10.1016/j.ijcard.2015.10.226

M3 - Article

C2 - 26618253

SN - 0167-5273

VL - 203

SP - 916

EP - 922

JO - International Journal of Cardiology

JF - International Journal of Cardiology

ER -